24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Insulin Doesn't Prevent Diabetes in Relatives of T1DM PatientsInsulin Pill May Delay Type 1 Diabetes in SomeHealth Tip: Diabetes Affects Women DifferentlySevere Psoriasis May Make Diabetes Increasingly LikelySpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityRisk of Falls Up With Mild, Moderate Diabetic RetinopathyFirst-Line Metformin Use for DM Up; Sulfonylurea Use DownPoor Prognosis for Diabetic Foot SoresER- Breast CA Risk Up for African-Americans With T2DMIn 2007-2014, Glycemic Control Plateaued in Diabetes PatientsDiabetes May Be Driving High Rates of Breast Cancer in Black WomenLeisure Time Exercise Linked to Reduced Mortality in T1DMAHA: Sudden Cardiac Death Risk Up for Young With DiabetesYounger People With Diabetes Have 7 Times Greater Risk of Sudden Heart DeathRisk of End-Stage Renal Disease Low With Type 1 DiabetesDrop in Incidence of End-Stage Renal Disease Due to DiabetesHealth Tip: Choosing Smarter FoodsLifestyle Changes Successfully Reduce Incidence of DiabetesNovel Method Developed for Estimating Prevalence of DiabetesNovel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DMKidney Failure Declining Among U.S. Diabetics: CDCACE Inhibitor, Statin No Benefit for T1DM, High Albumin ExcretionMagnesium, T2DM Link Seen in Poor-Carbohydrate-Quality DietRetinal Sensitivity Linked to Cognitive Status in T2DMKidney Damage Seen in Most Patients With Long-Lasting T1DArterial Stiffness Linked to Incidence of DiabetesUndiagnosed Diabetes Accounts for Small Portion of DiabetesNew Clinical Practice Guideline for Management of T2DMDiabetes Tied to Worse Outcomes in Heart Failure PatientsStatins May Raise Odds of T2DM in Those at High RiskFinancial Incentives Up Teen Glucose Monitoring AdherenceFewer Diabetes Cases Being MissedSudden Death Most Common CV Death in T2DM/ASCVDDiabetes Ups Risk of MACE in Acute Coronary SyndromesLifestyle, Metformin Interventions Have Variable EffectsHealth Tip: Best Grains And Starchy Veggies for DiabeticsGlycemic Control Up With Oral Semaglutide in Type 2 DiabetesCommercial Weight Management Program May Help Prevent T2DDiabetes Pill Might Replace Injection to Control Blood SugarNew Screening Tool Can Identify Diabetic RetinopathyRisk Conferred by T2D Modified by HbA1c in Heart FailureNo Causal Link Between Plasma Lipids, Diabetic RetinopathyBetter Glycemic Control With Insulin Pump for Youth With T1DPump May Beat Shots for Type 1 DiabetesWhere There's Type 1 Diabetes, Celiac Disease May FollowFlu Shot Key for People With DiabetesMaking Halloween a Treat for Kids With DiabetesPay for Performance Cuts Mortality in Diabetes PatientsAddition of DPP4i to AGI Reduces HbA1c in T2DM
Links
Related Topics

Medical Disorders

Fast-Acting Insulin Aspart Ups Glycemic Control in T1DM


HealthDay News
Updated: Apr 14th 2017

new article illustration

FRIDAY, April 14, 2017 (HealthDay News) -- Fast-acting insulin aspart improves glycemic control in type 1 diabetes, according to a study published online April 11 in Diabetes Care.

David Russell-Jones, M.B.B.S., M.D., from the Royal Surrey Country Hospital in Guildford, U.K., and colleagues examined the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in a multicenter phase 3 trial. Adults with type 1 diabetes were randomized to either double-blind mealtime faster aspart (381 adults), IAsp (380 adults), or open-label postmeal faster aspart (382 adults).

The researchers found that in both treatment groups, hemoglobin A1c (HbA1c) was reduced, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference: mealtime, −0.15 percent; postmeal, 0.04 percent). There was a statistically significant reduction in HbA1c for mealtime faster aspart versus IAsp (P = 0.0003). At one hour and two hours after the meal test, postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart (estimated treatment difference, −1.18 mmol/L and −0.67 mmol/L, respectively); for the two-hour PPG increment, superiority to IAsp was confirmed. Between treatments, the overall rate of severe or blood glucose-confirmed hypoglycemic episodes and safety profiles were similar.

"Faster aspart effectively improved HbA1c, and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Abstract/Full Text (subscription or payment may be required)